Posted by Michael Wonder on 29 Apr 2022
Rinvoq (upadacitinib) approved by U.S. FDA as an oral treatment for adults with active ankylosing spondylitis
29 April 2022 - Across the two pivotal trials, Rinvoq delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis patients achieving ASAS40 (51% and 44.5% with Rinvoq versus 26% and 18.2% with placebo) at week 14 compared to placebo.
AbbVie today announced that the U.S. FDA has approved Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumour necrosis factor blockers.
